241 related articles for article (PubMed ID: 22747953)
1. Multiple drug hypersensitivity reactions to anti-tuberculosis drugs: five cases in HIV-infected patients.
Lehloenya RJ; Wallace J; Todd G; Dheda K
Int J Tuberc Lung Dis; 2012 Sep; 16(9):1260-4. PubMed ID: 22747953
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons.
Lehloenya RJ; Todd G; Wallace J; Ngwanya MR; Muloiwa R; Dheda K
Br J Dermatol; 2016 Jul; 175(1):150-6. PubMed ID: 26918554
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions.
Lehloenya RJ; Todd G; Badri M; Dheda K
Int J Tuberc Lung Dis; 2011 Dec; 15(12):1649-57. PubMed ID: 22118173
[TBL] [Abstract][Full Text] [Related]
4. Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania.
Dukes CS; Sugarman J; Cegielski JP; Lallinger GJ; Mwakyusa DH
Trop Geogr Med; 1992 Oct; 44(4):308-11. PubMed ID: 1284179
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future.
Lehloenya RJ; Dheda K
Expert Rev Anti Infect Ther; 2012 Apr; 10(4):475-86. PubMed ID: 22512756
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults.
Okwera A; Johnson JL; Vjecha MJ; Wolski K; Whalen CC; Hom D; Huebner R; Mugerwa RD; Ellner JJ
Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099
[TBL] [Abstract][Full Text] [Related]
7. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon.
Kuaban C; Bercion R; Koulla-Shiro S
East Afr Med J; 1997 Aug; 74(8):474-7. PubMed ID: 9487410
[TBL] [Abstract][Full Text] [Related]
8. Adverse cutaneous drug eruptions and HIV: a clinician's global perspective.
Todd G
Dermatol Clin; 2006 Oct; 24(4):459-72, vi. PubMed ID: 17010776
[TBL] [Abstract][Full Text] [Related]
9. Clinical aspects and treatment outcome in HIV-associated pulmonary tuberculosis: an experience from a Thai referral centre.
Hongthiamthong P; Riantawan P; Subhannachart P; Fuangtong P
J Med Assoc Thai; 1994 Oct; 77(10):520-5. PubMed ID: 7745373
[TBL] [Abstract][Full Text] [Related]
10. A rare case of streptomycin-induced toxic epidermal necrolysis in a patient with tuberculosis: a therapeutic dilemma.
Hmouda H; Laouani-Kechrid C; Nejib Karoui M; Denguezli M; Nouira R; Ghannouchi G
Ann Pharmacother; 2005 Jan; 39(1):165-8. PubMed ID: 15546942
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of cutaneous drug eruptions in adult Nigerians with HIV/AIDS.
Salami TA; Asalu AF; Samuel SO
Niger Postgrad Med J; 2010 Jun; 17(2):160-3. PubMed ID: 20539333
[TBL] [Abstract][Full Text] [Related]
12. [Stevens-Johnson syndrome and toxic epidermal necrolysis after intake of rifampicin-isoniazid: report of 8 cases in HIV-infected patients in Togo].
Pitche P; Mouzou T; Padonou C; Tchangai-Walla K
Med Trop (Mars); 2005 Sep; 65(4):359-62. PubMed ID: 16548490
[TBL] [Abstract][Full Text] [Related]
13. Severe cutaneous adverse reactions due to isoniazid in a HIV positive patient.
Viswanath BK; Ranka P; Ramanjanayalu M
Indian J Lepr; 2012; 84(3):227-32. PubMed ID: 23484337
[TBL] [Abstract][Full Text] [Related]
14. Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases.
Lehloenya RJ; Muloiwa R; Dlamini S; Gantsho N; Todd G; Dheda K
J Antimicrob Chemother; 2015 Sep; 70(9):2648-51. PubMed ID: 26142408
[TBL] [Abstract][Full Text] [Related]
15. Treatment and prevention of tuberculosis in HIV-infected persons.
Cohn DL
Infect Dis Clin North Am; 1994 Jun; 8(2):399-412. PubMed ID: 8089467
[TBL] [Abstract][Full Text] [Related]
16. CD4 count and risk of anti-tuberculosis drug-associated cutaneous reactions in HIV-infected Thai patients.
Boonyagars L; Hirunwiwatkul P; Hurst CP
Int J Tuberc Lung Dis; 2017 Mar; 21(3):338-344. PubMed ID: 28225346
[TBL] [Abstract][Full Text] [Related]
17. Life-threatening acute adverse cutaneous drug reactions.
Wolf R; Orion E; Marcos B; Matz H
Clin Dermatol; 2005; 23(2):171-81. PubMed ID: 15802211
[TBL] [Abstract][Full Text] [Related]
18. [Cutaneous side effects due to psychiatric drugs].
Rebok F; Pérez Roldán ML; Daray FM
Vertex; 2008; 19(82):348-56. PubMed ID: 19424517
[TBL] [Abstract][Full Text] [Related]
19. Increased drug reactions in HIV-1-positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR).
Smith KJ; Skelton HG; Yeager J; Ledsky R; Ng TH; Wagner KF
Clin Exp Dermatol; 1997 May; 22(3):118-23. PubMed ID: 9425690
[TBL] [Abstract][Full Text] [Related]
20. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification.
Wolf R; Matz H; Marcos B; Orion E
Clin Dermatol; 2005; 23(3):311-4. PubMed ID: 15896547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
